Product Description
XW014 is a small molecule GLP-1 receptor agonist with the potential to be dosed orally once a day. (Sourced from: https://www.sciwindbio.com/pipeline)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sciwind Biosciences APAC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| XW014-001 | P1 |
Recruiting |
Type 2 Diabetes |
2025-02-01 |